

# MARIA SECRIER

---

CONTACT	University College London, UCL Genetics Institute	<i>Mobile:</i> +44-794-6074-078
INFORMATION	Department of Genetics, Evolution and Environment	<i>Email:</i> m.secrier@ucl.ac.uk
	Darwin Building, Gower Street, London WC1E 6BT	

---

## CURRENT POSITION

**Lecturer, Computational Cancer Biology** *11/2017 - present*  
*UCL Genetics Institute, Department of Genetics, Evolution and Environment, London, UK*  
• Research programme in computational cancer genomics and immunology.

---

## EDUCATION

**PhD, Computational Biology - *magna cum laude*** (4 publications, 3 first author) *10/2009 - 06/2013*  
*European Molecular Biology Laboratory (EMBL) and the University of Heidelberg, Germany*  
-Mentors: Dr. Reinhard Schneider, Dr. Wolfgang Huber  
• Thesis topic: Visualization and analysis strategies for dynamic gene-phenotype relationships

**BSc, Bioinformatics and Computational Biology** (2 publications, 1 first author) *08/2006 - 06/2009*  
*Jacobs University, Bremen, Germany*  
• Thesis topic: Mutational robustness in gene regulatory networks

---

## RESEARCH EXPERIENCE

**Senior Scientist: bioinformatics and immuno-oncology** *07/2016 - 10/2017*  
*AstraZeneca, Cambridge, UK*  
• Led projects in the area of immuno-oncology, disease bioinformatics and CRISPR-Cas9 screens.

**Visiting Scientist: cancer genomics** *07/2016 - 07/2017*  
*Cancer Research UK Cambridge Institute, Cambridge, UK*  
• Led the genomic analyses of the first ever derived oesophageal adenocarcinoma organoids.

**Research Associate: cancer genomics** *01/2014 - 07/2016*  
*Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK*  
- Mentors: Prof. Simon Tavaré, Prof. Rebecca Fitzgerald  
• Headed the computational analysis efforts of the group on whole-genome sequencing data from >100 samples of oesophageal adenocarcinoma, as part of the International Cancer Genome Consortium (ICGC).

**Short-term Postdoc: cancer bioinformatics** *07/2013 - 11/2013*  
*European Molecular Biology Laboratory (EMBL), Heidelberg, Germany*  
- Mentors: Dr. Reinhard Schneider, Dr. Wolfgang Huber, Dr. Toby Gibson  
• Evaluated the impact of perturbing motif-mediated protein interactions in different types of cancer.

**Research Assistant (multiple): bioinformatics and systems/network biology** *2007-2009*  
Imperial College (London), Max Planck Institute (Bremen), University of Maynooth (Ireland)

---

## HONOURS, AWARDS AND FUNDING

<b>Wellcome Institutional Strategic Support Fund</b> (£19,802 for 2 years)	<i>2018–2020</i>
<b>Wellcome Trust, BBSRC and BSGCT student bursaries</b> (£5,440)	<i>2018</i>
<b>Bye Fellowship, Murray Edwards College</b> , University of Cambridge	<i>2014–2016</i>
<b>Special Distinction for Excellency</b> at postgraduate level in Europe (from Romanian Government)	<i>2013</i>
<b>Graduate Research Fellowship, EMBL</b> , Heidelberg - funding for the duration of the PhD	<i>2009–2013</i>
<b>Merit-based Scholarship/Distinction for Academic Achievement</b> , Jacobs University	<i>2006–2009</i>

---

<b>Co-chair of the UCL Cancer Domain Early Careers Network</b>	<b>2018 - present</b>
<b>Senior Editor - Annals of Human Genetics</b>	<b>2017 - present</b>
<b>Member of the Cambridge Cancer Centre Aerodigestive Committee</b>	<b>2015 - 2016</b>
Established bioinformatic infrastructure/expertise as one of top 3 priorities for the Cambridge Cancer Centre.	
<b>Member of the Garuda Core Alliance Consortium - Systems Biology knowledge platform</b>	<b>2011 - 2013</b>

---

 SELECTED PUBLICATIONS (TOTAL - 18, FIRST AUTHOR - 6, † JOINT FIRST AUTHORSHIP)
 

---

- Li, X.†, Francies, H.†, **Secrier, M.**, .., Garnett, M. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. *Nat Commun* 2018; 9(1):2983
- Talukdar, F.R., di Pietro, M., **Secrier, M.**, .., Herceg, Z., OCCAMS Consortium\*. Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. *Ann N Y Acad Sci* 2018
- Noble, F., .., Underwood, T.J., **OCCAMS Consortium\***. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. *Br J Surg* 2017; 104(13):1816-1828 (\* includes **Secrier M**)
- Garcia, E., .., Underwood, T.J., **OCCAMS Consortium\***. Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. *Sci Rep* 2016; 6:32417. (\* includes **Secrier M**)
- Noorani, A.†, Bornschein, J.†, Lynch, A.G.†, **Secrier, M.**, .., Fitzgerald, R.C. A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. *Genome Res* 2017;27(6):902-912
- Secrier, M.**†, Li, X.†, .. Fitzgerald, R.C. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. *Nat Genetics* 2016; 48(10):1131-41
- Contino, G., Eldridge, M., **Secrier, M.**, .., Fitzgerald, R.C. Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. *F1000Res* 2016; 5:1336.
- Secrier, M.**, Fitzgerald, R.C. Signatures of mutational processes and associated risk factors in esophageal squamous cell carcinoma: a geographically independent stratification strategy? *Gastroenterology* 2016; 150(5):1080-3.
- De Silva, N., Schulz, L., Paterson, A., Qain, W., **Secrier, M.**, .., Fitzgerald, R.C., Ford, H. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. *Br J Cancer* 2015 Nov 3;113(9):1305-12.
- Ross-Innes, C.S., .., Fitzgerald, R.C., **OCCAMS Consortium\***. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. *Nat Genetics* 2015 Sep;47(9):1038-46. (\* includes **Secrier M**)
- Secrier, M.**, Schneider, R. Visualizing time-related data in biology, a review. *Brief Bioinform* 2014 Sep;15(5):771-82. *corresponding author*
- Weaver, J.M., .., Fitzgerald, R.C., **OCCAMS Consortium\***. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. *Nat Genetics* 2014 Aug;46(8):837-43. (\* includes **Secrier M**)
- Secrier, M.**, Schneider, R. PhenoTimer: Software for mapping time-resolved phenotypic landscapes. *PLOS ONE* 2013 Aug 12;8(8):e72361. *corresponding author*
- Secrier, M.**, Pavlopoulos, G.A., Aerts, J., Schneider, R. Arena3D: visualizing time-driven phenotypic differences in biological systems. *BMC Bioinform* 2012 Mar 22;13:45. *highly accessed, corresponding author*
- Setty, Y., Chen, C.C., **Secrier, M.**, .., Kalamatianos, D., Emmott, S. How neurons migrate: a dynamic in-silico model of neuronal migration in the developing cortex. *BMC Syst Biol* 2011 Sep 30;5:154.
- Pavlopoulos, G.A., **Secrier, M.**, .., Schneider, R., Bagos, P.G. Using graph theory to analyze biological networks. *BioData Min* 2011 Apr 28;4:10. *highly accessed*
- Secrier, M.**†, Toni, T.†, Stumpf, M.P. The ABC of reverse engineering biological signalling systems. *Mol Biosyst* 2009 Dec;5(12):1925-35.